<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39418214</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>41</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2023-June 2024.</ArticleTitle><Pagination><StartPage>909</StartPage><EndPage>916</EndPage><MedlinePgn>909-916</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7341a1</ELocationID><Abstract><AbstractText>Circulating vaccine-derived polioviruses (cVDPVs) can emerge and lead to outbreaks of paralytic polio as well as asymptomatic transmission in communities with a high percentage of undervaccinated children. Using data from the World Health Organization Polio Information System and Global Polio Laboratory Network, this report describes global polio outbreaks due to cVDPVs during January 2023-June 2024 and updates previous reports. During the reporting period, 74 cVDPV outbreaks were detected in 39 countries or areas (countries), predominantly in Africa. Among these 74 cVDPV outbreaks, 47 (64%) were new outbreaks, detected in 30 (77%) of the 39 countries. Three countries reported cVDPV type 1 (cVDPV1) outbreaks and 38 countries reported cVDPV type 2 (cVDPV2) outbreaks; two of these countries reported cocirculating cVDPV1 and cVDPV2. In the 38 countries with cVDPV2 transmission, 70 distinct outbreaks were reported. In 15 countries, cVDPV transmission has lasted &gt;1 year into 2024. In Nigeria and Somalia, both countries with security-compromised areas, persistent cVDPV2 transmission has spread to neighboring countries. Delayed implementation of outbreak response campaigns and low-quality campaigns have resulted in further international spread. Countries can control cVDPV outbreaks with timely allocation of resources to implement prompt, high-quality responses after outbreak confirmation. Stopping all cVDPV transmission requires effectively increasing population immunity by overcoming barriers to reaching children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Namageyo-Funa</LastName><ForeName>Apophia</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Sharon A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Traoré</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Shaukat</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bigouette</LastName><ForeName>John Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Jorba</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wiesen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bolu</LastName><ForeName>Omotayo</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Ousmane M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023321">Poliovirus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023321" MajorTopicYN="N">Poliovirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>13</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39418214</ArticleId><ArticleId IdType="pmc">PMC11486351</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7341a1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Estivariz CF, Burns CC, Macklin GR. Poliovirus vaccine–live [Chapter 50]. In: Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's vaccines (8th ed.). Philadelphia, PA: Elsevier; 2023:914–68.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Polio eradication strategy 2022–2026: delivering on a promise. Geneva, Switzerland: World Health Organization; 2021. https://polioeradication.org/wp-content/uploads/2022/06/Polio-Eradication-Strategy-2022-2026-Delivering-on-a-Promise.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Standard operating procedures: responding to a poliovirus event or outbreak, version 4. Geneva, Switzerland: World Health Organization; 2022. https://www.who.int/publications/i/item/9789240049154</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. OPV cessation. Geneva, Switzerland: World Health Organization; 2023. https://polioeradication.org/polio-today/preparing-for-a-polio-free-world/opv-cessation/</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. cVDPV2 outbreaks and the type 2 novel oral polio vaccine (nOPV2). Geneva, Switzerland: World Health Organization; 2024. https://polioeradication.org/wp-content/uploads/2024/08/GPEI_nOPV2_Factsheet_5-January-2024.pdf</Citation></Reference><Reference><Citation>Macklin GR, Peak C, Eisenhawer M, et al.; nOPV2 Working Group. Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine 2023;41(Suppl 1):A122–7. 10.1016/j.vaccine.2022.02.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigouette JP, Henderson E, Traoré MA, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2021–December 2022. MMWR Morb Mortal Wkly Rep 2023;72:366–71. 10.15585/mmwr.mm7214a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7214a3</ArticleId><ArticleId IdType="pmc">PMC10078846</ArticleId><ArticleId IdType="pubmed">37022974</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiger K, Stehling-Ariza T, Bigouette JP, et al. Progress toward poliomyelitis eradication—worldwide, January 2022–December 2023. MMWR Morb Mortal Wkly Rep 2024;73:441–6. 10.15585/mmwr.mm7319a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7319a4</ArticleId><ArticleId IdType="pmc">PMC11115430</ArticleId><ArticleId IdType="pubmed">38753550</ArticleId></ArticleIdList></Reference><Reference><Citation>Shet A, Carr K, Danovaro-Holliday MC, et al. Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories. Lancet Glob Health 2022;10:e186–94. 10.1016/S2214-109X(21)00512-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00512-X</ArticleId><ArticleId IdType="pmc">PMC8691849</ArticleId><ArticleId IdType="pubmed">34951973</ArticleId></ArticleIdList></Reference><Reference><Citation>Davlantes E, Jorba J, Henderson E, et al. Notes from the field: circulating vaccine-derived poliovirus type 2 emergences linked to novel oral poliovirus vaccine type 2 use—six African countries, 2021–2023. MMWR Morb Mortal Wkly Rep 2023;72:1041–2. 10.15585/mmwr.mm7238a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7238a4</ArticleId><ArticleId IdType="pmc">PMC10519714</ArticleId><ArticleId IdType="pubmed">37733626</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>